Related Experiment Video
Updated: Mar 17, 2026
06:18
Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
Published on: August 18, 2023
3.9K
Memory programming and new manufacturing paradigms in CAR-T cell therapy.
Niloufar Mohammadkhani1,2, Saber Ebrahimi3,4, Marzieh Hesam Mohammadi1,2
1Department of Medicine I, Medical Center-University of Freiburg and Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Germany.
Cancer Gene Therapy
|March 16, 2026
Summary
Strategies to enhance chimeric antigen receptor (CAR) T cell persistence are explored, balancing anti-tumor activity with potential toxicities. Emerging "off-the-shelf" CAR-T therapies may reduce the need for prolonged CAR-T cell survival.
Area of Science:
- Immunology
- Cell Therapy
- Oncology
Background:
- Chimeric antigen receptor (CAR) T cell therapy shows promise but is limited by short in vivo persistence.
- Strategies focus on enhancing CAR-T cell survival, often via memory phenotypes, to improve anti-tumor activity.
Purpose of the Study:
- To review recent advances in augmenting CAR-T cell persistence.
- To discuss the role of memory-associated features in CAR-T cell longevity.
- To highlight emerging "off-the-shelf" CAR-T platforms and their implications for persistence engineering.
Main Methods:
- Literature review of studies on CAR-T cell persistence.
- Analysis of strategies leveraging memory-like phenotypes.
- Evaluation of emerging "off-the-shelf" CAR-T technologies.
Main Results:
- Enhanced persistence can improve anti-tumor effects but may increase toxicity.
- Memory-like phenotypes are key targets for prolonging CAR-T cell survival.
- Novel "off-the-shelf" platforms offer potential for broad accessibility and timely treatment.
Conclusions:
- Context-specific approaches are needed for CAR-T cell persistence strategies.
- The development of "off-the-shelf" CAR-T cells may decrease the emphasis on engineering enhanced persistence.
- Future directions involve balancing efficacy, safety, and accessibility in CAR-T cell therapy development.
